OVERCOMING CANCER DRUG RESISTANCE

SCANDION ONCOLOGY

Q2 REPORT – 1/4 2023 – 30/6 2023

Scandion Oncology A/S – www.scandiononcology.com – CVR No. 38613391

> “Cost reduction measures means that Scandion is now funded into H2, 2024”
>
> **Francois R. Martelet**
> *CEO*

KEY FIGURES & FINANCIAL HIGHLIGHTS

TDKK	Q2 2023	Q1-Q2 2023	Q2 2022	Q1-Q2 2022	FY 2022
Income Statement					
Operating loss	-11,318	-23,292	-24,840	-41,152	-80,166
Net finance income/cost	66	131	-37	-288	-2,034
Loss before tax	-11,253	-23,160	-24,877	-41,440	-82,200
Net loss	**-8,774**	**-18,062**	**-23,021**	**-35,940**	**-76,700**
Total comprehensive loss	**-8,774**	**-18,062**	**-23,021**	**-35,940**	**-76,700**
Balance Sheet					
Total non-current assets	7,154	7,154	7,026	7,026	2,546
Total current assets	53,032	53,032	80,702	80,702	86,855
Hereof Cash and Cash equivalents	*45,709*	*45,709*	*72,667*	*72,667*	*77,605*
Total Assets	**60,186**	**60,186**	**87,728**	**87,728**	**89,401**
Total Equity	**52,265**	**52,265**	**67,769**	**67,769**	**70,327**
Cash Flow					
From Operating activities	-14,280	31,505	-14,251	-31,954	-69,443
From Investing activities	0	0	25	221	-389
From Financing activities	-196	-391	-1,072	-1,310	41,727
Net cash flow for the period	-14,476	-31,895	-15,298	-33,043	-28,105
Key ratios					
Equity ratio	87%	87%	77%	77%	79%
Earnings per share (EPS)	-0,22	-0,57	-0.72	-1.12	-1.88
Earnings per share (EPS-D)	-0,22	-0,57	-0.72	-1.12	-1.88
Shareholder EQT per share	1,28	1,28	2.11	2.11	1.74
Employees					
Average number of FTE	9	10	14	14	14
Number of FTE end of period	5	5	15	15	10
Shares, Outstanding end of period	**40,706,972**	**40,706,972**	**32,135,544**	**32,135,544**	**40,706,972**

HIGHLIGHTS DURING Q2 2023

ON APRIL 26, Scandion announced results of the Annual General Meeting.

HIGHLIGHTS AFTER THE END OF THE PERIOD

ON JULY 18, The European Patent Office announced intention to grant of Composition-of-Matter patent for Scandion Oncology's lead compound SCO-101. If granted, the patent will cover the commercial solid form of SCO-101 until at least 2042.

ON AUGUST 17, Data from PANTAX trial to be presented at ESMO Congress 2023.

TABLE OF CONTENTS

In this document, the following definitions shall apply unless otherwise specified: ***"the Company"*** or ***"Scandion"*** refers to **Scandion Oncology A/S**, CVR No. 38613391.

CEO LETTER

CONTINUED PATIENT RECRUITMENT, PROLONGED FUNDING AND ENHANCED PATENT PROTECTION

Cost reduction measures mean we are now funded into second half of 2024, and a successful patent application puts us on the brink of having almost 20 years of exclusivity on our lead compound SCO-101.

Scandion had a good second quarter of 2023 in which we continued to seamlessly execute our strategy and plans. We maintained strong momentum in the CORIST trial, reduced costs to extend our cash runway and significantly enhanced the patent protection of SCO-101, our lead compound. Further, we continued the pre-clinical research in Acute Myeloid Leukemia (AML) and results will be reported in H2, 2023 as previously communicated. All in all, it was another quarter with strong operational execution in which we made several efforts to de-risk our development pipeline.

> "A successful patent application puts us on the brink of having almost 20 years of exclusivity on our lead compound SCO-101"
>
> ***Francois R. Martelet***
> *CEO*

CORIST trial on track

We maintain our focus on primarily metastatic colorectal cancer with the CORIST phase IIa-trial investigating SCO-101 as a combination treatment in this indication. We are currently conducting part three of the trial in which we continue to escalate the dose of SCO-101 as we look for the optimal dose and signs of efficacy. We continue to enroll patients according to plan and are on track to publish topline results in the second half of 2023.

As a reminder, the ongoing part three of CORIST is a dose finding study with primary endpoints of the maximum tolerated dose, safety, and tolerability. Full safety information will be available later. We are encouraged to see signals of efficacy. A protocol amendment allowing to explore a shortened schedule of SCO-101 given over four days rather than six has been implemented. The aim is to increase the synergy of the drug combination optimizing the daily drug doses.

Bringing down costs

Since the capital raise in the summer of 2022, Scandion has held cash on hand to fund the company into 2024. We have now extended this cash runway into H2, 2024.

As a biotech company not generating cash, it is a permanent priority for us to extend our funding whenever possible. To this end we continuously exercise strict cost control and look for ways to limit our spending without jeopardizing the investments necessary for long-term value creation.

During the second quarter we were able to bring down our costs through reducing both our general spending and the number of positions in the company. Importantly, this has been done in a way that reduces our capacity but not our capabilities by leveraging external expertise. This lowers our running costs and improves our flexibility. We are used to operating in this way, and we are confident that it will continue to be effective and beneficial. With the different cost reduction measures extending our funding into H2, 2024, we have no imminent need to secure further funding, e.g., raise capital or obtain loans. Instead, we continue to focus on executing our plans to grow the value of SCO-101 through our research and development work. Given the difficult situation on the capital markets, especially for biotech companies this is a reasonable position to be in.

Unique improvement in patent protection

Perhaps equally important to the financial position for any biotech company is the protection of its intellectual property, first and foremost the patent protection of molecules in development. We have recently seen a significant and quite unique improvement in this area with patent protection – and thereby our exclusive use – of SCO-101 set to being expanded to at least 2042.

Scandion has applied for a Composition of Matter-patent for solid crystal forms of SCO-101, including the form of the molecule that we expect to market (pending successful completion of clinical development and subsequent approval). Based on the application, the European Patent Office in January issued a favorable patentability opinion and followed this up in July by announcing its intention to grant the patent. We anticipate this to happen before the end of 2023. Notice that there is no difference between the crystal form for which the positive intention to grant a patent has been received from the EPO and the crystal form which is used in all pivotal animal studies, prior phase I studies in healthy volunteers and ongoing studies PANTAX-Ib and CORIST. Therefore, no additional studies are needed since it is the same crystal form (drug substance). We envisage the new patent to provide protection of the commercial solid form of SCO-101 until its expiry in 2042 or later. This will put us in the favorable and unusual position of having a molecule in phase II of clinical development with almost 20 years of exclusivity ahead of us. Typically, a molecule in this stage of development might have 8-10 years of patent protection left.

The new patent would potentially improve the cash flow from SCO-101. This could also allow us to expand the development of the molecule into new indications, since we will have better opportunities to recoup our investments.

PANTAX data to be presented at ESMO

We expect to conduct a full analysis of all safety and efficacy outcomes from the PANTAX trial (SCO-101 in pancreatic cancer). We will present the topline results from PANTAX at the European Society for Medical Oncology (ESMO) Congress 2023 in October. This will be a great opportunity to make the safety data available to a large number of international physicians and other stakeholders.

Topline data from PANTAX were communicated on March 31, 2023. The primary endpoint was achieved, as the maximum tolerated dose of Scandion's lead compound SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer was established at 200 milligrams given for 6 consecutive days every 2 weeks. We plan to do the full analysis of the PANTAX data late in 2023 with the final results to be presented in the first half of 2024. This data will help us to plan potential further development in pancreatic cancer and/or other indications.

Potential gamechanger

Unfortunately, drug resistance remains a massive problem in cancer treatment and in the development of new medicines. If we can fulfil our mission of reverting the resistance and make treatments work better and longer, the benefits could be game changing for patients, relatives, health care professionals and society.

Scandion is one of only a few companies with a chance of providing these benefits through new innovative treatments. We want to improve the fate of patients losing the fight to cancer because of resistance towards current conventional chemotherapies. It is a pleasure for me to lead our team in this work, and I thank all our stakeholders – patients, staff, shareholders, and partners – for your continued support. I am pleased with our strong operational momentum and our efforts to de-risk the company.

Francois Martelet, M.D.
CEO

OUR VISION

To overcome cancer drug resistance in order to improve lives for cancer patients and their families

SCANDION ONCOLOGY AND THE THERAPY

THE COMPANY

Scandion Oncology is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options.

One of the most significant challenges in modern oncology is how to treat tumors that are or have become resistant to the prescribed anti-cancer drugs.

Scandion Oncology's most advanced innovative drug, SCO-101, is an oral drug that in preclinical studies has been documented to reverse resistance towards some of the most commonly used anti-cancer drugs.

SCO-101 is currently being tested in a clinical phase Ib and a phase II trial in cancer patients.

Scandion Oncology has additionally other products in its pipeline targeting cancer drug resistance, as future development opportunities.

All with the aim to be the Cancer Drug Resistance Company.

THE THERAPY

Almost all cancer patients with metastatic disease fail their cancer treatment – largely due to their cancer cells either being resistant already from the time of the primary diagnosis or because the cancer cells acquire resistance during anti-cancer treatment. As a result, the cancer continues to grow despite treatment and without any other effective drugs, the patients are left to fight the growing cancer on their own.

Therefore, drug resistance is a major threat to cancer patients and a huge burden on the health care systems. As such, it also presents a significant commercial opportunity for Scandion Oncology.

The global market for chemotherapy has a value of 37bn USD and is estimated to grow by 12 percent annually (CAGR) for the next five years.

An add-on therapy such as SCO-101 would be able to tap into a share of this market and reach adoption fast.

At Scandion Oncology we are not aware of any drugs that are registered for blocking anti-cancer drug resistance.

SCANDION ONCOLOGY IN BRIEF

OUR MISSION

To bring new medicines to patients in order to overcome cancer drug resistance and improve lives for cancer patients and their families

7,842

SHAREHOLDERS JUNE 30, 2023

46 MDKK

CASH POSITION JUNE 30, 2023

51 MSEK

MARKET CAP JUNE 30, 2023

1 PRE-CLINICAL PROGRAM
AML

2 CLINICAL PROGRAMS
CORIST currently in Phase II,
PANTAX currently in Phase Ib

PIPELINE
SCO-101 (~100 subjects dosed),
SCO-201
800 analogues

CANCER INDICATIONS
Colorectal, Pancreatic,
Acute Myeloid Leukemia and others

PEOPLE
Current, permanent staff of
5 employees as of June 30, 2023
Office in Copenhagen, Denmark

LISTED STOCK EXCHANGE
Nasdaq First North Stockholm

PIPELINE AND STRATEGY

CLINICAL PIPELINE

Developing First-in-Class Medicines for Personalized Therapy

Scandion Oncology is currently developing a unique first-in-class lead compound SCO-101 – an oral add-on therapy to standard anti-cancer treatment. The most advanced program, CORIST, is a clinical phase II study for the treatment of drug resistant metastatic colorectal cancer (mCRC). The second program, PANTAX, is a clinical phase Ib study for the treatment of unresectable or metastatic pancreatic cancer.

First-in-class medicine

There are currently no drugs on the market targeting cancer drug resistance, and SCO-101 has the potential to be first in this class of treatments and become the defining drug for a group of patients in very high need of medical innovation.

Personalized therapy

Scandion Oncology is developing predictive biomarkers in conjunction with the ongoing CORIST and PANTAX studies, to enable a personalized medicine approach for the use of SCO-101.

Scandion Oncology's Clinical Pipeline

Program	Compound	Indication	Discovery / Pre-clinical	Phase I	Phase II	Phase III
CORIST	SCO-101	Colorectal cancer	SCO-101 + FOLFIRI			
PANTAX	SCO-101	Pancreatic cancer	SCO-101 + nab-paclitaxel and gemcitabine			

ACHIEVED MILESTONES

- **PANTAX:** Dose finding results from phase Ib trial released end of Q1, 2023

UPCOMING KEY EVENTS

- **CORIST:** Recruitment part 3 completed H2, 2023
- **CORIST:** Dose finding results from part 3 is expected in H2, 2023
- **PANTAX:** Final analysis of data in H1, 2024
- **AML:** Pre-clinical data in H2, 2023

CORIST

For the Treatment of Patients with Metastatic Colorectal Cancer

In the CORIST phase II study, patients with chemotherapy resistant metastatic colorectal cancer (mCRC) receive SCO-101 treatment together with the standard chemotherapy drug combination FOLFIRI. All patients enrolled in the trial have previously demonstrated FOLFIRI resistance.

The first part of the CORIST phase II study, which aimed at establishing a safe dose of SCO-101 when given together with FOLFIRI has been successfully completed and positive interim results were presented in June 2021.

The interim results led Scandion to continue the second part of the CORIST phase II study (part 2) in RAS wild-type patients. This second part of the CORIST phase II study has completed recruitment of 25 patients, and continues the focus on safety, tolerability, and efficacy parameters, to establish initial proof-of-concept for SCO-101 in mCRC on a schedule combining SCO-101 and FOLFIRI.

Topline data from CORIST part 2 have been released end of Q3, 2022. The topline results confirmed the safety and tolerability of SCO-101 in this indication and combination. Further, tumor reductions were observed in some patients, however below the 30% threshold defined as the trial's primary endpoint. Also, indication of prolonged progression free survival and stable disease (secondary endpoints) were observed in this hard-to-treat refractory patient population.

Based on our learnings from the trial so far, CORIST part 3 and the subsequent part 4 are designed to provide an optimized way to dose SCO-101 and chemotheraphy to ensure maximum effect in patients with mCRC. We believe, that with the optimized dosing schedules in part 3, there is a better chance of increasing the SCO-101 and chemotherapy activity and thus meeting the efficacy endpoint of 30% tumor reduction and thereby demonstrating clinical proof of concept.

About the CORIST phase II study

The aim of the CORIST phase II study is to investigate SCO-101 in combination with chemotherapy (FOLFIRI) in patients with mCRC. Patients enrolled in the CORIST study have failed all prior standard chemotherapy and have entered a terminal stage of their disease with little hope of either a cure or of extending life further. Moreover, in most countries there are no further therapies to offer these patients.

CORIST part 1

The first part of the CORIST phase II study, which aimed at establishing a safe dose (maximum tolerated dose) of SCO-101 when given together with FOLFIRI has been successfully completed. SCO-101 was administered once daily on day 1 to day 6 and FOLFIRI was administered on day 5 to 7.

CORIST part 2

The second part of the CORIST phase II study only included patients with RAS wild-type tumors, based on findings in CORIST part 1. Part 2 of the CORIST study has completed recruitment of 25 patients, and continues the focus on safety, tolerability, and efficacy parameters, to establish initial proof-of-concept for SCO-101 on a schedule combining SCO-101 and FOLFIRI. Topline data from CORIST part 2 were released end of Q3, 2022.

CORIST part 3

CORIST part 3 will evaluate the safety and tolerability of SCO-101 in combination with FOLFIRI when dosed according to a different schedule than in part 1 and 2 of the CORIST phase II study.

CORIST part 3 is planned to include up to 36 mCRC patients with both RAS wild-type and RAS mutated tumors (up to 6 escalation cohorts with a traditional 3+3 design). The number of patients will vary according to the observed tolerance of the new schedule. Dose finding results from CORIST part 3 are expected in H2, 2023.

Depending of the outcome of CORIST part 3 we may plan another clinical proof of concept study (i.e. CORIST part 4) using the best dosing schedule and the right patient population in mCRC out of the CORIST part 3.

ABOUT THE DISEASE

Colorectal cancer (CRC) is one of the most common cancers worldwide with over 1.9 million new cases and 900,000 deaths estimated to occur every year. Unfortunately, a large proportion of patients diagnosed with CRC will develop metastatic disease (mCRC) despite prior adjuvant treatment and approximately 20% of newly diagnosed CRC patients have already developed metastatic disease at the time of diagnosis. The standard of care for patients with mCRC is either surgery and/or chemotherapy and targeted therapy with monoclonal antibodies.

For incurable patients, standard drugs are 5-FU and derivatives, oxaliplatin, irinotecan, bevacizumab and panitumumab or cetuximab. The anti-cancer agent irinotecan is most often prescribed in combination with 5-FU and leucovorin (FOLFIRI). One major problem in the treatment of mCRC is the frequent development of drug resistance. In practical terms, this means that the cancer continues to either grow during the anti-cancer treatment (de novo resistance) or re-grow after an initial response to the anticancer treatment (acquired resistance).

PANTAX

For the Treatment of Patients with Unresectable or Metastatic Pancreatic Cancer

In the PANTAX phase Ib study, patients with unresectable or metastatic pancreatic cancer receive SCO-101 treatment in combination with nab-paclitaxel and gemcitabine which is standard first- or second-line therapy.

The PANTAX phase Ib dose-finding study was initiated in Q4, 2020 and patients were enrolled from clinical sites in Denmark and Germany. In August 2022, Scandion announced that due to good tolerability the dosing was escalated to higher levels than expected based on the initial findings in the CORIST trial, which prompted the amendment of the PANTAX trial design communicated in January 2021. The continued dose escalation extended the PANTAX trial meaning it was expected to complete enrollment in H1, 2023.

Topline data from the PANTAX phase Ib study were given on March 31, 2023. The primary endpoint was achieved, as the maximum tolerated dose of Scandion's lead compound SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer was established at 200 milligrams given for 6 consecutive days every 2 weeks. The full analysis of all safety and efficacy outcomes will be performed after all patients have completed treatment and a follow up-period. Once the final data are available, Scandion will carefully assess and publish the final results before deciding potential next steps of development of SCO-101 as a combination treatment of pancreatic cancer.

About the PANTAX study

In the PANTAX study, patients with unresectable or metastatic pancreatic cancer receive SCO-101 treatment in combination with nab-paclitaxel and gemcitabine which is standard first- or second-line chemotherapy.

The aim of the phase Ib study is to establish a safe dose (maximum tolerated dose) of SCO-101 in combination with nab-paclitaxel and gemcitabine.

ABOUT THE DISEASE

Approximately 500,000 patients worldwide are newly diagnosed with pancreatic cancer each year. Pancreatic cancer has a very high unmet need, with poor prognosis and high treatment failure rates, leading to 466,000 deaths worldwide in 2020. Despite the comparably low incidence, it is the 3rd leading cause of cancer death in the US and 7th worldwide. Approximately 70% of diagnosed patients have a life expectancy of less than 1 year without adequate treatment and patients with metastatic disease (50-55%) have a limited survival of only 3 to 6 months.

The treatment paradigm for pancreatic cancer is predominantly composed of chemotherapies, most notably FOLFIRINOX or gemcitabine and nab-paclitaxel. Pancreatic cancer has a high frequency of primary (de novo) resistance against chemotherapy, but also fast development of secondary (acquired) resistance is a major problem. This means that most patients who initially experience a positive effect of the chemotherapy, will experience disease progression relatively fast.

PRE-CLINICAL PIPELINE

Building Future Value

Scandion Oncology's Pre-clinical Pipeline

Program	Compound	Indication	Discovery / Pre-clinical	Phase I	Phase II	Phase III
HEMATOLOGY	SCO-101	AML / MDS				
201	SCO-201	Solid tumors				

We believe that SCO-101 could potentially revert resistance to chemotherapy also within blood cancer and Acute Myeloid Leukemia (AML). Relapse of disease is a big issue for many patients and often the relapse is caused by drug resistance. This could be tied to ABCG2 that SCO-101 specifically inhibits. As we are the only company with this kind of specific inhibitor in clinical development, we may be in a unique position to offer new and better treatments for AML and potentially other blood cancers.

SCANDION ONCOLOGY INTELLECTUAL PROPERTY

Scandion Oncology is diligently expanding and strengthening the Company's portfolio of intellectual property rights providing valuable long term commercial exclusivities.

At the end of Q2, 2023, Scandion Oncology owned a portfolio of thirteen patent families, taking effect in commercially relevant countries.

Changes to Scandion Oncology's patent portfolio will be updated continuously and will be summarized in the Company's quarterly reports.

IP related events of high strategic value for the Company will be announced through press releases.

IP PORTFOLIO UPDATE

- **ONE NEW INTERNATIONAL PATENT APPLICATION FILED**
- **ON JULY 18, THE EUROPEAN PATENT OFFICE ANNOUNCED INTENTION TO GRANT OF COMPOSITION-OF-MATTER PATENT FOR SCANDION ONCOLOGY'S LEAD COMPOUND SCO-101.**

  IF GRANTED, THE PATENT WILL COVER THE COMMERCIAL SOLID FORM OF SCO-101 UNTIL AT LEAST 2042.

FINANCIAL REVIEW

Results of operations

Other operating income, mainly funding from Innovation Fund Denmark amounted to 0.5 MDKK (0.0). Total operating expenses in Q2, 2023 reached 11.8 MDKK (24.8), a decrease of 13.0 MDKK compared to Q2, 2022, which reflects the restructurings and savings implemented in H2, 2022 and H1 2023, along with reductions in clinical costs.

Operating expenses can be divided into two main cost groups, Research & Development and General & Administration expenses. Research & Development expenses in Q2, 2023 of 8.3 MDKK (19.9), relate to the two ongoing clinical studies, CORIST and PANTAX. General & Administration expenses in Q2, 2023 amounted to 3.5 MDKK (5.0).

Operating loss for Q2, 2023 was 11.3 MDKK (24.8).

In Q2, 2023, net financial items amounted to 0.1 MDKK (0.1), which mainly derives from interest and currency adjustments.

The total comprehensive loss for the period is 8.8 MDKK (23.0).

Financial position

Total assets as of June 30, 2023, were 60.2 MDKK (87.7). Hereof, cash and cash equivalents amounted to 45.7 MDKK (72.7).

Receivables amounted to 7.3 MDKK (8.0) which mainly relates to income tax receivables in the amount of 5.5 MDKK (5.5) to be received in November 2023. Other receivables and prepayments amounts to 1.8 MDKK (2.5).

The equity ratio as of June 30, 2023 was 87% (77%), and equity was 52.3 MDKK (67.8).

Cash flow and Cash Position

The cash flow from operating activities in Q2, 2023 was an outflow of 14.3 MDKK (14.3) and is explained by the loss before tax and working capital. The cash flow from investing activities was an outflow of 0.0 MDKK (0.0). The cash flow from financing activities was an outflow of 0.2 MDKK (1.1).

Hence, the total net cash flow for Q2, 2023 was a net cash outflow of 14.5 MDKK (15.3) leaving the company with a cash position of 45.7 MDKK as of June 30, 2023.

With the cash position as of June 30, 2023, Scandion Oncology is sufficiently capitalized to fund ongoing activities well into 2024.

(Numbers in brackets represent the corresponding reporting period last year)

SHAREHOLDER INFORMATION

The share

The shares of Scandion Oncology A/S are listed on Nasdaq First North Growth Market Sweden.

Scandion Oncology's share capital amounts to 2,992 TDKK divided into 40,706,972 shares of nominal value 0.0735 DKK each. There is only one class of shares, and each share represents one vote.

As of June 30, 2023, the number of shares was 40,706,972 (32,135,544).

Listing	First North Growth Market Sweden
Number of shares	40,706,972 (32,135,544)
Share price (June 30, 2023)	1.26 SEK (8.37 SEK)
Market capitalization (June 30, 2023)	51 MSEK (269 MSEK)
Ticker	SCOL
ISIN	DK0061031895

Shareholders by country, June 30, 2023



Source: Monitor by Modular Finance AB.

Shareholders

There are no individual shareholders that own 5% or more of the shares in Scandion Oncology as of June 30, 2023.

According to the shareholder register maintained by Euroclear Sweden AB, Scandion Oncology had 7,842 (8,157) shareholders as of June 30, 2023.

Share-based incentive schemes

At the Annual General meeting on April 27, 2022 a new warrant program was approved, authorizing the Board of Directors to issue up to 4,177,620 new warrants which carry the right to subscribe for an equal number of shares in Scandion Oncology A/S. As of June 30, 2023 a total of 482,033 warrants has been issued to the Board of Directors and a total of 2,339,066 warrants has been issued to the Executive Management and Employees - a grand total of 2,821,099 warrants granted.

Share price

The Scandion Oncology share price on June 30, 2023 was 1.26 SEK, equivalent to a market capitalization of 51 MSEK.

Relative to Q2, 2022, the average, daily turnover of Scandion Oncology shares decreased from 1.2 MSEK in Q2, 2022 to 0.6 MSEK in Q2, 2023 equivalent to a decrease of 50%.

(Numbers in brackets represent the corresponding reporting period last year)

12 month share price development and trading volume, July 1, 2022 to June 30, 2023

Source: Cision/Millistream

PUBLIC PRESENTATIONS IN 2023

Date	*Event*
Oct 10, 2023	LSX Nordic Congress, CEO Francois R. Martelet will take part in panel discussion.
Oct 20-24, 2023	Data from PANTAX trial to be presented at the ESMO Congress 2023 in Madrid.

ANALYST COVERAGE

Scandion Oncology is covered by the following analysts:

Redeye AB
(Christian Binder)

CORPORATE MATTERS

FINANCIAL CALENDAR

November 22, 2023 Interim report Q3
February 27, 2024 Year-end report 2023

Forward looking statements

This financial report includes statements that are forward-looking, and actual future results may differ materially from those stated. In addition to the factors explicitly commented upon, other factors that may affect the actual future results are for example development within research programs, including development in pre-clinical and clinical trials, the impact of competing research programs, the effect of economic conditions, the effectiveness of the company's intellectual property rights and preclusions of potential second party's intellectual property rights, technological development, exchange rate and interest rate fluctuations and political risks.

For further information, please contact

Johnny Stilou, CFO
T: +45 29 60 35 32
E: jos@scandiononcology.com

The information was provided by the contact person above for publication on August 23, 2023 at 08.30 CET.

Certified Advisor

Västra Hamnen Corporate Finance AB

STATEMENT BY THE BOARD OF DIRECTORS

The Board of Directors provides their assurance that the Q2 2023 report provides a fair and true overview of the Company's operations, financial position, and results.

Copenhagen, August 23, 2023
The Board of Directors of Scandion Oncology A/S

Martin Møller	*Chairman of the Board*
Jørgen Bardenfleth	*Deputy chairman of the Board*
Keld Flintholm Jørgensen	*Member of the Board of Directors*
Alejandra Mørk	*Member of the Board of Directors*
Martine J. van Vugt	*Member of the Board of Directors*

The interim report has not been audited or reviewed by the company's auditors.

FINANCIAL STATEMENTS

INCOME STATEMENT

TDKK	Q2 2023	Q1-Q2 2023	Q2 2022	Q1-Q2 2022	FY 2022
Other operating income	510	684	0	90	2,057
Research and development expenses	-8,321	-17,111	-19,876	-32,998	-65,065
General and administration expenses	-3,507	-6,865	-4,964	-8,244	-17,158
Operating loss	**-11,318**	**-23,292**	**-24,840**	**-41,152**	**-80,166**
Financial items					
Financial income	335	670	201	214	932
Financial expenses	-269	-539	-238	-502	-2,966
Loss before tax	**-11,253**	**-23,160**	**-24,877**	**-41,440**	**-82,200**
Tax	2,478	5,098	1,856	5,500	5,500
Net loss for the period	**-8,774**	**-18,062**	**-23,021**	**-35,940**	**-76,700**
Other comprehensive income for the period	0	0	0	0	0
Total comprehensive loss	**-8,774**	**-18,062**	**-23,021**	**-35,940**	**-76,700**

BALANCE SHEET

TDKK	Q1-Q2 2023	Q1-Q2 2022	FY 2022
Assets			
Non-current assets			
Equipment	568	447	659
Right of use assets	1,198	789	1,597
Deposits	290	290	290
Income Tax receivables	5,098	5,500	0
Total Non-current assets	**7,154**	**7,026**	**2,546**
Current Assets			
Prepaid expenses and accrued income	712	787	727
Other receivables	1,111	1,748	3,024
Income Tax receivables	5,500	5,500	5,500
Cash and cash equivalents	45,709	72,667	77,605
Total current assets	**53,032**	**80,702**	**86,855**
Total Assets	**60,186**	**87,728**	**89,401**
Equity and liabilities			
Equity			
Share capital	2,992	2,362	2,992
Share premium reserved	233,008	190,270	233,008
Retained earnings	-183,735	-124,863	-165,673
Total equity	**52,265**	**67,769**	**70,327**
Non-current liabllities			
Lease liabilities	603	500	820
Other liabilities	941	1,390	0
Total non-current liabilities	**1,544**	**1,890**	**820**
Current liabilities			
Lease liabilities	603	305	776
Account liabilities	2,361	10,954	4,895
Other liabilities	3,412	6,810	12,583
Total current liabilities	**6,377**	**18,069**	**18,254**
Total equity and liabilities	**60,186**	**87,728**	**89,401**

EQUITY

1/1 2023 – 30/6 2023 TDKK	Share capital	Share premium	Retained earnings	Total equity
Balance at January 1, 2023	**2,992**	**233,008**	**-165,673**	**70,327**
Comprehensive loss				
Result for the period			-18,062	-18,062
Net comprehensive loss			**-18,062**	**-18,062**
Transaction with owners				
Net transactions with owners	**0**	**0**	**0**	**0**
Balance at June 30, 2023	**2,992**	**233,008**	**-183,735**	**52,265**

1/7 2022 – 31/12 2022 TDKK	Share capital	Share premium	Retained earnings	Total equity
Balance at July 1, 2022	**2,362**	**190,270**	**-124,863**	**67,769**
Comprehensive loss				
Result for the period			-40,760	-40,760
Net comprehensive loss			**-40,760**	**-40,760**
Transaction with owners				
Increase of Capital	630	52,914		53,544
Expenses related to capital increase		-10,176		-10,176
Share-based compensation expenses			-50	-50
Net transactions with owners	**630**	**42,738**	**-50**	**42,436**
Balance at December 31, 2022	**2,992**	**233,008**	**-165,673**	**70,327**

1/1 2022 – 30/6 2022 TDKK	Share capital	Share premium	Retained earnings	Total equity
Balance at January 1, 2022	**2,362**	**191,152**	**-88,973**	**104,541**
Comprehensive loss				
Result for the period			-35,940	-35,940
Net comprehensive loss			**-35,940**	**-35,940**
Transaction with owners				
Expenses related to capital increase		-882		-882
Share-based compensation expenses			50	50
Net transactions with owners	**0**	**-882**	**50**	**-832**
Balance at June 30, 2022	**2,362**	**190,270**	**-124,863**	**67,769**

CASH FLOW STATEMENT

TDKK	Q2 2023	Q1-Q2 2023	Q2 2022	Q1-Q2 2022	FY 2022
Operating activities					
Result before tax	-11,253	-23,160	-24,877	-41,440	-82,200
Non-cash sharebased payments	0	0	0	52	0
Financial items, reversed	-66	-131	37	288	2,034
Depreciation, reversed	245	490	213	425	882
Change in working capital	-3,272	-8,835	10,413	9,008	6,375
Cash flow from operating activities before financial items	**-14,345**	**-31,636**	**-14,214**	**-31,666**	**-72,909**
Interest and exchange rate gains	335	670	322	469	932
Interest and exchange rate losses	-269	-539	-359	-757	-2,966
Corporate tax received	0	0	0	0	5,500
Cash flow from operating activities	**-14,280**	**-31,505**	**-14,251**	**-31,954**	**-69,443**
Investing activities					
Tangible assets	0	0	0	196	-414
Financial assets	0	0	25	25	25
Cash flow from investing activities	**0**	**0**	**25**	**221**	**-389**
Financing activities					
Contributed capital	0	0	0	0	53,545
Expenses related to capital increase	0	0	-882	-882	-11,058
Lease payments	-196	-391	-190	-428	-760
Cash flow from financing activities	**-196**	**-391**	**-1,072**	**-1,310**	**41,727**
Net cash flow for the period	**-14,476**	**-31,895**	**-15,298**	**-33,043**	**-28,105**
Cash and cash equivalents beginning of the period	60,185	77,605	87,965	105,710	105,710
Cash and cash equivalents end of the period	**45,709**	**45,709**	**72,667**	**72,667**	**77,605**

NOTES

NOTE 1:
GENERAL INFORMATION

Scandion Oncology A/S (the "Company"), Corporate Registration Number DK-38613391, is a limited liability company, incorporated and domiciled in Denmark. The Company is listed at Nasdaq First North Growth Market under the ticker SCOL and the ISIN code DK0061031895. The registered office is at Fruebjergvej 3, 2100 Copenhagen, Denmark.

NOTE 2:
ACCOUNTING POLICIES

Basis for Preparation
The interim financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting, as adopted by EU and the additional requirements for submission of interim reports for companies listed on Nasdaq First North Growth Market Sweden.

The interim financial statements are presented in Danish kroner (DKK) which is the functional currency of the Company. All values are presented in thousand DKK and all amounts are rounded to the nearest thousand DKK

New IFRS standards & interpretations
There are no IFRS standards and interpretations issued before the end of this reporting period of relevance for the Company, which are expected to change current accounting regulation significantly.

Foreign currency translation
On initial recognition, foreign currency transactions are translated at the exchange rate at the transaction date. Receivables, liabilities and other monetary items denominated in foreign currency that have not been settled at the balance sheet date are translated at closing rates.

Foreign exchange differences between the rate of exchange at the date of the transaction and the rate of exchange at the date of payment or the balance sheet date, respectively, are recognized in the income statement under financial items.

Definitions
Earnings per share (EPS) and diluted earnings per share (EPS-D) are calculated in accordance with IAS 33.

Other key ratios are calculated in accordance with the online version of "Recommendations and Ratios " issued by The Danish Finance Society and CFA Society Denmark.

EQUITY RATIO:

$$\frac{\text{Equity (end of year)} * 100}{\text{Total assets}}$$

EARNINGS PER SHARE BASIC (EPS):

$$\frac{\text{Net result}}{\text{Average number of shares in circulation}}$$

DILUTED EARNINGS PER SHARE (EPS-D):

$$\frac{\text{Net result}}{\text{Diluted average number of shares in circulation}}$$

SHAREHOLDERS' EQUITY PER SHARE:

$$\frac{\text{Equity}}{\text{Number of shares, year end}}$$

NOTE 3:
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

In preparing the interim financial statements, management makes various accounting judgements and estimates and define assumptions, which form the basis of recognition, measurement and presentation of the company's assets and liabilities.

The estimates and assumptions applied are based on historical experience, the most recent information available at the reporting date, and other factors that management considers reasonable under the circumstances.

The basis for judgements and information can by nature be inaccurate or incomplete, and the Company is subject to uncertainties, which can result in an actual outcome that deviates from estimates and defined assumptions. It may be necessary in the future to change previous estimates and judgements as a result of supplementary information, additional knowledge and experience or subsequent events.

In applying the Company's accounting policies described in note 2, management has exercized critical accounting judgements and estimates, which significantly influence on the amounts recognized in the financial statements.

NOTE 4:
RISK MANAGEMENT

Various risk factors may have an adverse impact on Scandion Oncology's operations and therefore the Company's results and financial position. For Scandion Oncology the main operational impact is potential delays in clinical trials as sites could be restricted from patient enrollment, or changes in requirements from authorities.

*A description of Scandion Oncology's risk exposure and risk management is included in the Annual Report 2022, note 18, page 51 ff. (please see **www.scandiononcology.com**).*

NOTE 5:
WARRANT PROGRAM

Warrant Program

At the Annual General meeting on April 27, 2022 a new warrant program was approved, authorizing the Board of Directors to issue up to 4,177,620 new warrants which carry the right to subscribe for an equal number of shares in Scandion Oncology A/S.

As of June 30, 2023 a total of 417,762 warrants has been issued to the Board of Directors and a total of 2,339,066 warrants has been issued to the Executive Management and Employees – giving 2,756,828 warrants issued in total.

Exercise price/strike price for the warrants is SEK 22.00. The fair value of the warrant program is zero and calculated in accordance with the Black-Scholes option pricing model.

Outstanding at January 1, 2023	2,221,099
Granted	600,000
Cancelled	-64,271
Outstanding at June 30, 2023	**2,756,828**

NOTE 6:

CONTINGENT ASSETS AND LIABILITIES

License and Collaboration Agreements

Scandion is not yet entitled to potential milestone payments and royalties on successful commercialization of products developed under license and collaboration agreements with potential partners.

Pending commercial litigation

Scandion is not involved in commercial litigations arising out of the normal conduct of its business.

NOTE 7:

RELATED PARTIES

Apart from salaries and warrants there were no significant transactions with Management or Board of Directors.

NOTE 8:

SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

No significant events have occured after the end of the reporting period.

SCANDION ONCOLOGY

Scandion Oncology A/S – Symbion Fruebjergvej 3 – DK 2100 Copenhagen – Denmark
www.scandiononcology.com – CVR No. 38613391